Cargando…

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

INTRODUCTION: A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term effects of lurasidone in patients with schizophrenia. METHODS: In the DB trial, patients were randomised to receive lurasidone or risperidone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Preeya J., Weidenfeller, Christian, Jones, Andrew P., Nilsson, Jens, Hsu, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140059/ https://www.ncbi.nlm.nih.gov/pubmed/33098548 http://dx.doi.org/10.1007/s40120-020-00221-4

Ejemplares similares

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
por: Mattingly, Greg W., et al.
Publicado: (2020)

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021)

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
por: Miura, Itaru, et al.
Publicado: (2022)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
por: Costamagna, Isabella, et al.
Publicado: (2021)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
por: Harvey, Philip D., et al.
Publicado: (2016)

Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
por: Najarian, D., et al.
Publicado: (2023)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
por: Calisti, F., et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
por: Najarian, Dean, et al.
Publicado: (2023)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
por: Tocco, M., et al.
Publicado: (2021)

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
por: Smilde, Bernard J., et al.
Publicado: (2022)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY
por: Ketter, Terence A., et al.
Publicado: (2016)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2017)

Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
por: Iyo, Masaomi, et al.
Publicado: (2021)

The clinical utility of lurasidone in schizophrenia: patient considerations
por: Harvey, Philip D
Publicado: (2015)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
por: Riva, Marco Andrea, et al.
Publicado: (2021)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
por: Guilera, Teresa, et al.
Publicado: (2023)

Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study
por: Arnold, Lesley M., et al.
Publicado: (2016)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
por: Javed, Afzal, et al.
Publicado: (2019)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
por: Meltzer, Herbert Y., et al.
Publicado: (2020)

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

M48. IS METABOLIC SYNDROME RELATED TO COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA? RESULTS FROM A DOUBLE-BLIND, ACTIVE-CONTROLLED, LURASIDONE STUDY
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
por: Giron‐Hernandez, Cesar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hm6b73jc8j07o30iklhmbtq519